# Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

> **NCT00485758** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 796 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** ER niacin/laropiprant
- **DRUG:** Comparator : placebo (unspecified)

## Key facts

- **NCT ID:** NCT00485758
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 796 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485758, "Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00485758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*